News

The companies expect to commence Phase 1 study of the AMP-110 immune modulation therapy, which targets autoimmune diseases by blocking inflammatory T cell differentiation, in the first half

The trial will also evaluate the effect of the drug on glucose and insulin resistance. Rhythm chief development officer Liz Stoner said the Phase 2 study is expected

Double-blind trial is being conducted in collaboration with the Friedreich’s Ataxia Research Alliance (FARA) Clinical Research Network and FARA’s Patient Registry. FARA President Ronald Bartek said the organisation

The double-blind, placebo-controlled study randomized 151 patients with either one of two doses of PRT-201, or placebo to evaluate the safety and efficacy of PRT-201 delivery subsequent to

Under the license, VABIOTECH is expected to develop and commercialize JE vaccine in Vietnam, Cambodia and Myanmar. In addition, VABIOTECH will provide certain development-based milestone payments to Inviragen.

The companies are developing long-acting PHT101 (PGC-C12E-Terlipressin) for once-daily subcutaneous injection dosing in outpatient populations. PharmaIN president Elijah Bolotin said, "We are excited about the medical potential of

The odorless OxyHives relief spray, which is absorbed into the blood stream faster, provides immediate relief than the conventional creams or ointments. The spray solution, which is launched

The research deal that is scheduled for three years will employ GlycoVaxyn’s bio-conjugation technology. GlycoVaxyn co-founder and chief scientific officer Michael Wacker said bacterial pathogens existing in multiple

The patent protects claims related to the technology which has the ability to electronically process, display and distribute eligible prescription savings on the medications and therapies, which healthcare